Radius Health is One of Farallon Capital’s Best 2014 Bets

Radius Health is One of Farallon Capital’s Best 2014 Bets

Radius Health Inc. (NASDAQ:RDUS), MacroGenics Inc. (NASDAQ:MGNX) and Caesars Entertainment Corp. (NASDAQ:CZR) started the week off strong, making notable gains on the market this Monday. Altisource Portfolio Solutions (NASDAQ:ASPS), Gilead Sciences Inc. (NASDAQ:GILD) and EXCO Resources Inc. (NYSE:XCO), on the other hand, are taking tumbles.

Sign up for our free daily newsletter

After A Tough Year, Odey Asset Management Finishes 2021 On A High

For much of the past decade, Crispin Odey has been waiting for inflation to rear its ugly head. The fund manager has been positioned to take advantage of rising prices in his flagship hedge fund, the Odey European Fund, and has been trying to warn his investors about the risks of inflation through his annual Read More

Radius Health Surges

Radius Health Inc. climbed +16.59% today after announcing positive results from one of its drug candidates. The company has been one of Farallon Capital’s best bets of the year. The hedge fund initiated a stake in the firm during the second quarter of the year and as of the third quarter still holds 950,000 RDUS shares. The stock has climbed more than +350% in 2014.


MacroGenics Inc. rallied +11.41% this Monday after inking a deal with Johnson & Johnson that could potentially be worth $700 million. The biotech company, a two-quarter George Soros holding, has gained +88.66% over the past three months.

Caesars Entertainment ended the day with an +11.19% gain on the heels of news that it will acquire Caesars Acquisition Company, one of its publicly traded subsidiaries. Leon Cooperman, John Paulson and George Soros have positions in the casino giant, which is down -30.36% year-to-date.

Altisource Portfolio Solutions Plummets Following Chairman’s Exit

Altisource Portfolio Solutions tumbled -33.47% this Monday after announcing that its Chairman of the Board is stepping down. The marketplace and transactions services provider is one of Leon Cooperman’s internationally-headquartered investments. Its price has tumbled -80% this year.

Gilead Sciences slid -14.34% today in the wake of reports that Express Scripts will cover only AbbVie’s newly-approved hepatitis C regimen – not those made by Gilead or Johnson & Johnson. Julian Robertson holds 440,000 GILD shares as of Q3 and is likely taking a hit here, given that the biopharmaceutical company has a 12% allocation in his public equity portfolio.

Long-time Wilbur Ross pick EXCO Resources dipped -11.19%. Just last week, the oil and gas company said it plans to suspend cash dividends. The stock has fallen -38.62% in the past month alone.

Sign up for our free daily newsletter


Updated on

No posts to display